Skip to main content

Percutaneous Tibial Nerve Stimulation

Percutaneous tibial nerve stimulation (PTNS) is a minimally invasive neuromodulation therapy primarily used for overactive bladder (OAB) and urgency urinary incontinence, with more uncertain evidence for fecal incontinence and chronic pelvic pain. AUA/SUFU 2024 permits minimally invasive OAB therapy through shared decision-making without required prior behavioral or drug trials , and recommends offering PTNS after inadequate response to or intolerance of behavioral therapy or medication .[2] The EAU female LUTS guideline strongly recommends PTNS as an option for symptomatic OAB/UUI in women.[1][2][3][21]

Implantable tibial stimulation and Sacral Neuromodulation have separate procedure and device pages because implantation and maintenance differ. The AUA/SUFU 2024 guideline groups PTNS, implanted tibial systems, SNM and Intradetrusor OnabotulinumtoxinA as minimally invasive choices rather than a mandatory third-line ladder.[2]

Mechanism of Action​

PTNS delivers retrograde electrical stimulation to the sacral nerve plexus (S2–S4) via the posterior tibial nerve, a mixed sensory-motor nerve that shares common nerve roots with the pelvic floor and bladder.[4][21] The exact mechanism remains incompletely understood, but research suggests stimulation modulates central and peripheral neural pathways involved in bladder control. Animal studies indicate that recruitment of unmyelinated C-fibers mediates the bladder-inhibitory effects, and co-activation of the adjacent saphenous nerve may also contribute.[5][6][7]

Technique and Protocol​

The Urgent PC instructions for use (UPC 200-B, international edition, English section) and a university-hospital standardized procedure describe the same office technique.[27][28]

  • Site: lower inner leg, about three fingerbreadths (5 cm) cephalad to the medial malleolus and about one fingerbreadth (2 cm) posterior to the tibia. The patient sits or lies supine.
  • Needle: clean the skin, then set the needle and guide-tube assembly at a 60° angle to the skin with the tip pointing cephalad. Tap through the skin, remove the guide tube and advance with a rotating motion, keeping the 60° angle and a path parallel to the tibia. About 2 cm of needle ends up in the leg. The Urgent PC kit supplies two 34-gauge needles, one for each leg.
  • Surface electrode: on the medial aspect of the calcaneus of the same leg. The lead wire connects to the stimulator and the clip to the needle.
  • Test mode: raise the current slowly until the patient has a motor response (toe flex or fan, or foot extension) or a sensory response (tingling toward the heel, arch or toes). Then lower the current by one level and start therapy.
  • No response: stop, reposition the needle slightly and repeat. If that fails, discard the needle and use the second one on the other leg.
  • Removal: disconnect the clip, remove the needle in one motion and press on the site if it bleeds.

Stimulation parameters (Urgent PC; the NURO 510(k) summary reports the same waveform, pulse width and frequency for NURO and lists Urgent PC as its predicate):[24][27]

  • Waveform and frequency: square wave, fixed 20 Hz
  • Pulse width: fixed 200 μs
  • Current: 19 adjustable levels from 0 to 9 mA (level 1 is 0.15 mA, level 11 is 5.0 mA). The patient's own threshold sets the therapy level. The 0.5–9 mA range in the SUmiT protocol (as summarized by AUA/SUFU) is a trial description, not a device setting.[2]
  • Session duration: therapy mode times out at 30 minutes. The IFU warns against longer sessions and advises that the patient stay seated or supine until the session ends.
  • Treatment course: 12 sessions, typically weekly. The IFU advises no decision to stop before the 12th session. In responders the interval is lengthened slowly, and if symptoms return the last effective schedule is resumed.[8][9][10][27][28]

Other systems differ in hardware. NURO (Advanced Uro-Solutions, K132561, cleared November 2013) has a rechargeable lithium battery, a permanently attached lead wire and downloaded therapy credits. Urgent PC uses a 9 V alkaline battery and a single-use lead wire with a fuse that limits it to one session. The 510(k) summary states the therapy protocol and waveform are equivalent. Follow the applicable manufacturer manual for any other system.[24][27]

The effect is relatively short-lived, and ongoing maintenance treatments (typically monthly or as needed) are required to sustain benefit.[1][9]

Clinical Indications​

  • Overactive bladder (OAB): the primary and best-supported indication, including urgency, frequency, nocturia, and urgency urinary incontinence
  • Neurogenic OAB: transcutaneous and percutaneous tibial stimulation studies in multiple sclerosis report improved bladder-diary and patient-reported LUT/OAB measures, whereas the effect in Parkinson's disease remains unclear[9][23]; in related transcutaneous evidence, a small randomized trial of tibial nerve stimulation in 24 men with post-stroke neurogenic OAB and no prior urinary symptoms (stimulation twice weekly for 6 weeks versus general advice and stretching sessions) reported improved urgency, frequency and subjective symptoms in the stimulation group, with urinary frequency superior to control and the effect reported to persist at 12 months[29]
  • Fecal incontinence: studied but with mixed results (see below)
  • Chronic pelvic pain or interstitial cystitis: evidence is limited and varies by syndrome. A review reported lower symptom improvement in IC/BPS than in other indications with PTNS and SNM; a separate 2013 review reported one sham-controlled RCT in men with category IIIB CP/CPPS in which 18/45 (40%) PTNS recipients had >50% pain improvement at 12 weeks.[11][12] The AUA IC/BPS guideline describes one prospective study of 12 weekly PTNS sessions in 20 women with refractory IC/BPS symptoms, which found no significant change in pain, symptom indices or voiding; the study sits in the discussion of its neuromodulation statement (Statement 21, Option, Grade C), whose conclusion names only sacral and pudendal stimulation.[25] EAU 2026 rates PTNS as probably effective for primary prostate pain syndrome (level 1b) and weakly recommends it for chronic primary anal pain syndrome (level 3).[26] AUA 2025 does not currently recommend PTNS for CP/CPPS because the positive trials have methodological limitations; this appears in its ungraded Future Directions discussion.[31]

Efficacy for Overactive Bladder​

The SUmiT trial (n=220), a multicenter double-blind sham-controlled RCT, demonstrated that 54.5% of PTNS patients reported moderate or marked improvement on the 13-week global response assessment versus 20.9% with sham (p < 0.001), with better diary frequency, nocturia, urgency and urgency incontinence outcomes.[13]

The STEP study followed 50 patients who had responded to 12 weekly treatments through a 14-week tapering protocol and then an investigator-and-patient treatment plan; 35 remained at 24 months. With a mean of 1.3 treatments per month, diary frequency, urgency incontinence episodes, nighttime voids and moderate-to-severe urgency episodes remained significantly improved from baseline at 6, 12, 18 and 24 months, and five mild adverse events of unknown relation to treatment were reported. The cohort was uncontrolled and limited to initial responders.[32]

A meta-analysis of 28 studies (n=2,461) reported a pooled success rate of 68% (95% CI 59–78%), with significant reductions in voiding frequency (−2.48/day), nocturia (−1.57/day), urgency episodes (−2.20/day), and incontinence episodes (−1.37/day).[14]

Comparison with Other Therapies​

ComparisonKey findingsEvidence
PTNS vs. ShamMore global responders (54.5% vs. 20.9%) and better 12-week diary outcomes for frequency, nocturia, urgency and UUI (SUmiT)[13]
Tibial nerve stimulation (percutaneous or transcutaneous) vs. antimuscarinicsIn women, the EAU panel's review found posterior tibial nerve stimulation techniques more effective for reducing UUI episodes, with no significant difference in overall symptom score, frequency or urgency (level 1a). A pooled analysis of tibial nerve stimulation found fewer adverse events and lower discontinuation rates than antimuscarinics; in the EAU review, adding an antimuscarinic to PTNS produced no statistically significant additional reduction in symptom score, frequency, nocturia or UUI episodes[2][3][15][21]
PTNS vs. Sacral NeuromodulationIn a network meta-analysis, SNM produced the greatest reductions in incontinence episodes and voiding frequency; long-term comparisons are lacking[16]
PTNS vs. OnabotulinumtoxinABoth improve OAB symptoms; botulinum toxin has more UTI and retention risk. TROOP was a nonrandomized cohort of women: among 97 of 150 enrollees who completed 3 months, its composite PGII/OAB-q cure rate was 50% with botulinum toxin versus 44.2% with PTNS (p=0.56); the botulinum toxin cohort had larger improvements in OAB-q urgency and UUI item scores (both p=0.02), although baseline symptom severity differed and the analyzed sample was smaller than the planned 80 patients per group. Sherif randomized 60 adults and reported greater benefit with botulinum toxin at 9 months after a 12-week PTNS course[2][16][33]
PTNS/TTNS vs. inactive or mixed conservative comparatorsPooled PTNS/TTNS reduced daily voiding frequency more than sham, placebo, no treatment or conservative management; this analysis does not provide a PFMT-specific comparison[20]

The current EAU female LUTS guideline recommends offering posterior tibial nerve stimulation as an option for OAB/UUI symptom improvement .[21] EAU also grades maintenance P-PTNS as effective for up to three years (level 2a) and transcutaneous PTNS as not inferior to percutaneous PTNS for urgency, frequency and quality of life (level 1a), noting that the optimal schedule has not been established.[21] AUA/SUFU 2024 recommends offering tibial stimulation, SNM and/or botulinum toxin after inadequate response or intolerance and separately permits choosing minimally invasive therapy without required prior conservative trials.[2]

Efficacy for Fecal Incontinence​

Evidence for PTNS in fecal incontinence is mixed. A prospective cohort study (n=150) showed improved FI scores in the 115 patients analyzed at a median 26 months (range 12–42) with maintenance sessions; the effect waned between sessions and the study was uncontrolled.[17] However, the CONFIDeNT trial (n=227), a large double-blind RCT, found no significant difference in the diary-complete groups after 12 weekly treatments: 39/103 (38%) with PTNS versus 32/102 (31%) with sham achieved ≥50% reduction in weekly FI episodes (p=0.396).[8] Similarly, the NOTABLE trial (n=166 women) found that PTNS did not differ from sham stimulation for FI severity.[18] A smaller RCT did show a modest advantage for PTNS over sham in reducing median FI episodes.[19] The international Urgent PC instructions list fecal incontinence as an indication alongside urgency, frequency and urge incontinence, whereas the NURO 510(k) indication is limited to OAB symptoms; check the labeling in your region.[24][27]

Safety and Adverse Effects​

PTNS typically has a favorable short-term safety profile; needle-site pain, minor inflammation or bleeding are possible. With Urgent PC, monitor for pain or skin irritation during stimulation and discontinue the session if discomfort occurs; its needle, surface electrode and lead are single-use.[13][22][27] Serious device-related events were not reported in the cited major OAB trial. Office PTNS leaves no implanted metal, unlike implantable tibial systems; an MRI assessment still needs to account for any other implanted hardware.[13][22]

Contraindications​

Screen against the chosen system's actual labeling. Medtronic NURO labeling, for example, excludes pacemakers or implantable defibrillators, a tendency to excessive bleeding, nerve damage affecting the tibial nerve or pelvic-floor function, and pregnancy or planned pregnancy. It also says not to use the device where treatment-site skin is compromised, and advises caution in patients with cardiac conditions.[22] Pelvic radiation history or lower-tract malignancy alone are not listed as universal NURO contraindications in the manufacturer's short safety statement.[22] The Urgent PC instructions list the same three contraindications and pregnancy, and add that the stimulator is not for intracardiac or transthoracic use, that concurrent medical monitoring equipment is not recommended, and that it must not be used with flammable anesthetic mixtures.[27] Listed risks are pain or throbbing at or near the site, bleeding, redness, possible peripheral nerve damage, toe numbness and stomach ache. Do not apply it to inflamed, infected or compromised skin. A university standardized procedure lists the same contraindications and cautions about cardiac pacing issues.[28]

Limitations and Practical Considerations​

  • Short-lived effect requiring ongoing maintenance sessions, which can be burdensome[1][9]
  • Patient compliance is limited by the need for weekly in-office visits during induction[1]
  • Coverage and visit limits vary by payer and policy
  • These limitations have driven the development of implantable tibial nerve stimulation devices, at least two of which have received FDA marketing authorization, offering at-home stimulation with the same mechanism of action[1]
  • PTNS and SNM have different targets and stimulation patterns.

Transcutaneous Alternative (TTNS)​

Transcutaneous tibial nerve stimulation (TTNS) uses surface electrodes rather than a needle and can be performed at home. Against sham or conservative comparators, meta-analysis shows TTNS and PTNS each reduce voiding frequency by similar amounts (about 3 voids/day), though the evidence is more limited and the same analysis found no significant improvement in incontinence episodes.[20] A 2025 meta-analysis of adults with OAB found fewer incontinence episodes with 10-Hz TTNS versus control/sham (3 RCTs; n=255; mean difference −1.24 episodes, 95% CI −2.09 to −0.39); the subgroup was small.[34] In a double-masked, sham-controlled randomized trial of 100 ambulatory women with UUI, 12 weeks of TTNS did not detect a between-group difference in OAB-q symptom-severity change (−19.5 versus −19.4; p=1.0) or the proportion with ≥50% fewer UUI episodes (58.8% versus 41.7%; p=0.2).[35] The AUA/SUFU guideline classes TTNS as a non-invasive therapy and cites a meta-analysis (Yang et al.) that found PTNS and TTNS similar for frequency, nocturia, urgency and incontinence episodes after inadequate response to other treatment.[2] TTNS may reduce office-visit burden for some neurological patients, but its urinary benefit is population-dependent; the EAU Neuro-Urology guideline says more reliable randomized evidence is needed and the effect in Parkinson disease remains unclear.[9][23] EAU Neuro-Urology 2026 judges tibial nerve stimulation and TENS possibly effective and safe in neurogenic LUTD but needing better RCTs; home percutaneous and transcutaneous tibial stimulation improved bladder-diary and patient-reported outcomes in multiple sclerosis but not detrusor-sphincter dyssynergia, and the effect in Parkinson disease remains unclear.[23] In a randomized trial of 100 patients with neurogenic detrusor overactivity secondary to spinal cord injury, adhesive skin-surface tibial stimulation for 4 weeks and solifenacin each improved bladder-diary parameters significantly from baseline at 2 and 4 weeks, with no significant difference between the two arms; no unanticipated adverse events were reported with stimulation.[30]

See Also​

Podcasts​

Exploring Neuromodulation: Sacral vs Tibial Approaches
BackTable Urology, Ep. 318 (2026) · Tracey Wilson, Kenneth Peters
backtable.com

Videos​

Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder
HCA Florida Healthcare (2022)

References​

1. Lee UJ, MacDiarmid S, Matthews CA, Gillespie E, Peters KM. "Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices." Adv Ther. 2024;41(7):2635-2654. doi:10.1007/s12325-024-02864-3

2. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985

3. Farag F, Sakalis VI, Arteaga SM, et al. "What Are the Short-Term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the EAU Female Non-Neurogenic LUTS Guidelines Panel." Eur Urol. 2023;84(3):302-312. doi:10.1016/j.eururo.2023.05.014

4. Stewart F, Gameiro LF, El Dib R, et al. "Electrical Stimulation With Non-Implanted Electrodes for Overactive Bladder in Adults." Cochrane Database Syst Rev. 2016;12:CD010098. doi:10.1002/14651858.CD010098.pub4

5. Li X, Li X, Liao L. "Mechanism of Action of Tibial Nerve Stimulation in the Treatment of Lower Urinary Tract Dysfunction." Neuromodulation. 2024;27(2):256-266. doi:10.1016/j.neurom.2023.03.017

6. Paquette JP, Yoo PB. "Recruitment of Unmyelinated C-Fibers Mediates the Bladder-Inhibitory Effects of Tibial Nerve Stimulation in a Continuous-Fill Anesthetized Rat Model." Am J Physiol Renal Physiol. 2019;317(1):F163-F171. doi:10.1152/ajprenal.00502.2018

7. Elder CW, Yoo PB. "A Finite Element Modeling Study of Peripheral Nerve Recruitment by Percutaneous Tibial Nerve Stimulation in the Human Lower Leg." Med Eng Phys. 2018;53:32-38. doi:10.1016/j.medengphy.2018.01.004

8. Knowles CH, Horrocks EJ, Bremner SA, et al. "Percutaneous Tibial Nerve Stimulation Versus Sham Electrical Stimulation for the Treatment of Faecal Incontinence in Adults (CONFIDeNT): A Double-Blind, Multicentre, Pragmatic, Parallel-Group, Randomised Controlled Trial." Lancet. 2015;386(10004):1640-8. doi:10.1016/S0140-6736(15)60314-2

9. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720-32. doi:10.1016/S1474-4422(15)00070-8

10. Zomkowski K, Kammers I, Back BBH, et al. "The Effectiveness of Different Electrical Nerve Stimulation Protocols for Treating Adults With Non-Neurogenic Overactive Bladder: A Systematic Review and Meta-Analysis." Int Urogynecol J. 2022;33(5):1045-1058. doi:10.1007/s00192-022-05088-7

11. Tutolo M, Ammirati E, Heesakkers J, et al. "Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-Neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature." Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002

12. Biemans JM, van Balken MR. "Efficacy and Effectiveness of Percutaneous Tibial Nerve Stimulation in the Treatment of Pelvic Organ Disorders: A Systematic Review." Neuromodulation. 2013;16(1):25-33. doi:10.1111/j.1525-1403.2012.00504.x

13. Peters KM, Carrico DJ, Perez-Marrero RA, et al. "Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT Trial." J Urol. 2010;183(4):1438-43. doi:10.1016/j.juro.2009.12.036

14. Wang M, Jian Z, Ma Y, et al. "Percutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome: A Systematic Review and Meta-Analysis." Int Urogynecol J. 2020;31(12):2457-2471. doi:10.1007/s00192-020-04429-8

15. Xia L, Yan H, Sun Y, et al. "Pooled Analysis of the Efficacy and Safety of Tibial Nerve Stimulation Versus Antimuscarinic Agents in the Management of Overactive Bladder Syndrome." Medicine. 2021;100(45):e27745. doi:10.1097/MD.0000000000027745

16. Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. "Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis." Toxins. 2020;12(2):E128. doi:10.3390/toxins12020128

17. Hotouras A, Murphy J, Walsh U, et al. "Outcome of Percutaneous Tibial Nerve Stimulation (PTNS) for Fecal Incontinence: A Prospective Cohort Study." Ann Surg. 2014;259(5):939-43. doi:10.1097/SLA.0b013e3182a6266c

18. Zyczynski HM, Richter HE, Sung VW, et al. "Percutaneous Tibial Nerve Stimulation vs Sham Stimulation for Fecal Incontinence in Women: NeurOmodulaTion for Accidental Bowel Leakage Randomized Clinical Trial." Am J Gastroenterol. 2022;117(4):654-667. doi:10.14309/ajg.0000000000001605

19. van der Wilt AA, Giuliani G, Kubis C, et al. "Randomized Clinical Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Electrical Stimulation in Patients With Faecal Incontinence." Br J Surg. 2017;104(9):1167-1176. doi:10.1002/bjs.10590

20. Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama'I MS, et al. "Efficacy of Percutaneous and Transcutaneous Posterior Tibial Nerve Stimulation on Idiopathic Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome: A Systematic Review and Meta-Analysis." Neurourol Urodyn. 2022;41(2):539-551. doi:10.1002/nau.24864

21. European Association of Urology. Guidelines on Non-neurogenic Female LUTS, disease management §4.1.4.a.5.d.1 and recommendations (Limited Update March 2026). Guideline.

22. Medtronic. NURO Percutaneous Tibial Neuromodulation—Indications, Safety, and Warnings, Rev 0915 (manufacturer short statement, not the complete technical manual). Safety statement.

23. European Association of Urology. EAU Guidelines on Neuro-Urology (Limited Update March 2026). Section 3.4.2.b, peripheral temporary electrostimulation. Official guideline.

24. US Food and Drug Administration. 510(k) Summary K132561: NURO Neuromodulation System (Advanced Uro-Solutions), decision November 5, 2013. FDA 510(k) summary.

25. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome." J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756

26. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology; limited update March 2026. Guideline

27. Cogentix Medical. Urgent PC Stimulator Instructions for Use, UPC 200-B (multilingual international edition; English section, pp 3-17). Manufacturer document.

28. UC San Diego Health. Standardized Procedure: Percutaneous Tibial Nerve Stimulation/PTNS (Adults), revised 2016. Institutional protocol for advanced practitioners, not a manufacturer IFU.

29. Monteiro ÉS, de Carvalho LB, Fukujima MM, Lora MI, do Prado GF. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology. 2014;84(3):509-14. doi:10.1016/j.urology.2014.05.031

30. Chen G, Liao L, Li Y. The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2015;47(3):451-5. doi:10.1007/s11255-015-0911-6

31. American Urological Association. Diagnosis and Management of Male Chronic Pelvic Pain (Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Chronic Scrotal Content Pain): AUA Guideline (2025). Approved March 2025. Full 2025 guideline Future Directions, p43.

32. Peters KM, Carrico DJ, MacDiarmid SA, Wooldridge LS, Khan AU, McCoy CE, et al. "Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study." Neurourol Urodyn. 2013;32(1):24-29. doi:10.1002/nau.22266

33. Kopcsay KS, et al. "Treatment of refractory overactive bladder with OnabotulinumtoxinA vs PTNS: TROOP trial." Int Urogynecol J. 2022;33(4):851-860. doi:10.1007/s00192-021-05030-3

34. Vaca-Benavides DA, Ju W, Gonzalez C, et al. "The importance of electrical parameters on transcutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis." Age Ageing. 2025;54(7):afaf203. doi:10.1093/ageing/afaf203

35. Shah NM, Lukacz ES, Ferrante KL, Menefee SA. "Transcutaneous Tibial Nerve Stimulation for Urge Incontinence: A Randomized Clinical Trial." Urogynecology (Phila). 2025;31(3):225-233. doi:10.1097/SPV.0000000000001616